Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
8 studies found for:    AGS-003
Show Display Options
Rank Status Study
1 Active, not recruiting A Rollover Protocol for Subjects Previously Treated With AGS-003
Condition: Renal Cell Carcinoma
Intervention: Drug: AGS-003
2 Recruiting A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer (NSCLC)
Interventions: Biological: AGS-003-LNG;   Drug: Carboplatin;   Drug: Abraxane;   Drug: Alimta;   Drug: Cisplatin;   Drug: Taxol;   Radiation: Radiation Therapy
3 Active, not recruiting Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)
Conditions: Advanced Renal Cell Carcinoma;   Renal Cell Carcinoma;   Metastatic Renal Cell Carcinoma
Interventions: Drug: Standard Treatment;   Biological: AGS-003
4 Not yet recruiting Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery
Conditions: Infiltrating Bladder Urothelial Carcinoma;   Stage II Bladder Urothelial Carcinoma;   Stage III Bladder Urothelial Carcinoma;   Stage IV Bladder Urothelial Carcinoma
Interventions: Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Procedure: Radical Cystectomy;   Biological: Tumor Cell-Derived Vaccine Therapy
5 Recruiting Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer
Conditions: Recurrent Renal Cell Carcinoma;   Stage I Renal Cell Cancer;   Stage II Renal Cell Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Procedure: Nephrectomy;   Biological: Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003
6 Completed Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment
Condition: Renal Cell Carcinoma
Interventions: Biological: AGS-003;   Drug: Sunitinib
7 Completed Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer
Condition: Renal Cell Carcinoma
Intervention: Biological: AGS-003
8 Recruiting RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)
Conditions: Metastatic Renal Cell Carcinoma;   Genitourinary Cancer (Bladder, Prostate or Testicular)
Intervention: Device: RNA extraction and amplification from biopsy specimens

Indicates status has not been verified in more than two years